Stille AB (STIL) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Stille AB SEK 128, price SEK 253, upside -49.1%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Stille AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 94.20 – kr 276.00 · fair‑value band kr 63.66 – kr 170.47 · the kr 252.50 price screens above the kr 128.47 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Stille in your weekly email
Every Wednesday you see whether Stille is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Stille AB develops, manufactures, and distributes medtech products in Sweden, Germany, the United Kingdom, Switzerland, North America, the United States, and internationally. It operates through the Surgical Instruments and Surgical Tables segments.
Show more
Stille AB develops, manufactures, and distributes medtech products in Sweden, Germany, the United Kingdom, Switzerland, North America, the United States, and internationally. It operates through the Surgical Instruments and Surgical Tables segments. The Surgical Instruments segment offers surgical scissors, including SuperCut, eye, blepharoplasty, operating, vascular, tenotomy, and face-lift scissors; colon, gall duct, multi-purpose, tangential occlusion, peripheral vascular, and anastomosis clamps; skin and nerve hooks, retractors, rib spreaders, self-retaining and trachea retractors, and nasal specula; and dressing, diathermy, knot-holding, tissue, iris, dura, and vascular forceps under the STILLE, Fehling, S&T, and Surgical Holdings brands. Its Surgical Tables segment provides C-arm tables, which are surgical tables used in advanced imaging, cardiac electrophysiology, cardiovascular and vascular, gastrointestinal and abdominal, interventional radiology, neuro/spine, pain management, and pulmonary under the imagiQ and MedStone brands. The company also offers instrument care education, repair and maintenance, and inspection services. Stille AB was founded in 1841 and is headquartered in Torshälla, Sweden.
Stock analysis
Stille AB (STIL) currently trades at kr 252.50, while our model-based Fair Value estimate is kr 128.47, implying the stock looks roughly 96.5% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of kr 160.10 per share, and 1 of the 24 models we run sit above the kr 252.50 price.
Bear case: the Growth DCF group reads lowest at kr 41.99, and 23 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: kr 63.66 (bear) to kr 170.47 (bull), the price of kr 252.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Stille AB reported revenue of 568M SEK in FY2025 versus 187M SEK in FY2021, a compound +32.0%/yr. Reported net income was 55.7M SEK in FY2025, compounding +36.4%/yr from FY2021.
Key figures
Market cap 2.3B SEK (≈ $229M) · P/E ratio 36.6 · P/S ratio 3.60 · EPS (TTM) kr 6.89 · Net margin 9.8% · Return on equity 8.8% · Return on assets (EBIT) 8.0% · Operating margin 16.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 73% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −49%, STIL screens richer than that median.
Fair Value models
Bear kr 63.66Fair Value kr 128.47Bull kr 170.47
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (kr 5.06 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.8%
Start year 2020 (pandemic). Over 10 years: +21.1% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+14.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.1%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.14% vs 11%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 13%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+53.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +50.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside−49% · Below median
Profitability
Return on equity (TTM)9% · Above median
Return on assets6% · Above median
Net margin (TTM)10% · Above median
Operating margin (TTM)17% · Above median
Growth and dividend
Revenue growth39% · Top 25%
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (TTM)36.6× · Pricier than median
P/B3.20× · Pricier than median
P/S (TTM)3.68× · Pricier than median
P/FCF14.7× · Pricier than median
EV/EBITDA19.9× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)100· sector 31
PAST (return on equity)35· sector 25
HEALTH (low debt)95· sector 96
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Stille AB Fair Value". https://www.fairvalue-calculator.com/stock/STIL
Frequently asked questions
Is Stille AB (STIL) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 128.47 versus a price of kr 252.50, about −49% upside (overvalued).
What is the fair value of STIL?
Our model-based fair value for Stille AB is kr 128.47 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 252.50.
What is the quality score of STIL?
Stille AB has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Stille AB (STIL)?
Our model-based price target is the fair value of kr 128.47 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario kr 63.66, optimistic scenario kr 170.47. It is a calculation from audited fundamentals, not an analyst target.
What is the Stille AB stock forecast for 2026?
Our models put fair value at kr 128.47, about −49% upside versus a price of kr 252.50 (overvalued). Cautious scenario kr 63.66, optimistic scenario kr 170.47. The calculation is refreshed regularly with new filings.
What is the revenue of Stille AB (STIL)?
Stille AB reported trailing-twelve-month revenue of about 617M SEK (latest available figure, as of Sep 24, 2026).
What growth is priced into Stille AB (STIL)?
For today's price to be fair in a discounted-cash-flow model, Stille AB would have to grow free cash flow by +53.1 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +31.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of STIL use?
Our models discount Stille AB at 11.0 %: a base by market capitalisation (micro), damped by beta 0.38, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Stille AB that is +53.1 % per year a year over ten years, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Stille AB (STIL) delivered so far?
Over the past 5 years revenue at Stille AB grew +31.8 % a year. The price currently implies +53.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Stille AB (STIL) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Stille AB (+53.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Stille AB (STIL)?
The free-cash-flow yield on the price is 0.69 %: that much free cash flow Stille AB produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Stille AB (STIL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Stille AB it is kr 128.47 per share (as of Sep 24, 2026), against a price of kr 252.50. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Stille AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, STIL trades above its calculated fair value: price kr 252.50, fair value kr 128.47, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of STIL?
No. The price is what the market pays today (kr 252.50); the fair value is what the company's own numbers justify (kr 128.47). For Stille AB the two are kr 124.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Stille AB worth?
The market values Stille AB at about 2.3B SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 252.50; our models calculate a fair value of kr 128.47 per share.
What do the bullish and bearish scenarios say about STIL?
Our models span a range for Stille AB: cautious scenario kr 63.66, base kr 128.47, optimistic kr 170.47 per share (as of Sep 24, 2026, price kr 252.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of STIL?
Stille AB trades at a price-to-earnings ratio of 36.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 128.47 is built from several models across several years. Other multiples: P/B 3.2, P/S 3.7, EV/EBITDA 19.9.
How solid is the balance sheet of Stille AB (STIL)?
Balance-sheet figures for Stille AB (as of Sep 24, 2026): return on equity 8.8%, debt of 0.09 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is STIL from its 52-week high?
Stille AB trades at kr 252.50, about 9% below its 52-week high of kr 276.00 and 73% above the low of kr 146.00 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of kr 128.47 is for.
Which stocks are comparable to Stille AB?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Stille AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 252.50, calculated fair value kr 128.47 (−49%), Quality Score 39/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of STIL calculated?
We run Stille AB through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 128.47, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Stille AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Stille AB (STIL)?
The closing price on Sep 23, 2026 was kr 252.50. Our model-based fair value is kr 128.47, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Stille AB right now?
The price sits above even our optimistic bull case (kr 170.47). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (kr 63.66 to kr 170.47). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Where does the earnings growth of Stille AB (STIL) come from?
Earnings per share at Stille AB grew +13.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +14.8 %, EBIT margin +4.9 %, tax rate −1.8 %, residual (interest, one-offs) −4.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Stille AB
How large is the market capitalisation of Stille AB (STIL)?
The market capitalisation of Stille AB is 2.3B SEK (≈ $229M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Stille AB (STIL)?
The price-to-sales ratio of Stille AB is 3.60 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Stille AB (STIL)?
Earnings per share at Stille AB are kr 6.89 (price ÷ EPS = P/E 36.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Stille AB (STIL)?
The net margin of Stille AB is 9.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Stille AB (STIL)?
The return on equity (ROE) of Stille AB is 8.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Stille AB (STIL)?
On an EBIT basis the return on assets of Stille AB is 8.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Stille AB (STIL)?
The operating margin of Stille AB is 16.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Stille AB (STIL)?
Revenue at Stille AB is growing +38.5% versus a year earlier (3y avg +32.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Stille AB (STIL)?
Earnings per share at Stille AB are growing +43.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Stille AB (STIL) carry?
The net debt of Stille AB is 4.6M SEK (fiscal year 2025, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Stille AB in the live analysis
One click puts Stille AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
